Human Adipose Tissue 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibition Without Tachyphylaxis by Clofutriben, a Pseudo‐Irreversible Enzyme Inhibitor
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Guohua An und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Iowa, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: 11-beta-Hydroxysteroid Dehydrogenase Type 1, Adipose Tissue, Enzyme Inhibitors, Pyridines. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Inhibitors of 11β‐hydroxysteroid dehydrogenase type 1 (HSD‐1), the pre‐receptor regulator of intracellular active glucocorticoid levels, have promise to treat glucocorticoid excess whether endogenous (neoplastic or physiological elevated cortisol) or iatrogenic (glucocorticoid medicine toxicity). Three structurally distinct HSD‐1 inhibitors have shown tachyphylaxis of pharmacodynamic activity in adipose, a key target tissue, suggesting that the clinical utility of the class might be limited by that pharmacological phenomenon. To determine whether the potent inhibitor clofutriben also showed adipose tachyphylaxis, HSD‐1 activity was measured during daily oral clofutriben administration and infusion of mass‐labeled enzyme substrate (cortisone) via microdialysis catheters placed in subcutaneous abdominal adipose of 12 persons with type 2 diabetes and obesity. During initial dosing, clofutriben was associated with dose‐dependent decreases of mass‐labeled HSD‐1 product (cortisol) in adipose dialysate, from < 25% at 1 mg to > 90% at 6–10 mg. At steady state, all clofutriben doses were associated with > 90% decreases of mass‐labeled cortisol in adipose dialysate with no evidence of tachyphylaxis. By surface plasmon resonance, clofutriben showed fast‐on, slow‐off (residence time 535 s) binding to human HSD‐1. Molecular docking revealed that clofutriben can form a ternary complex with nicotinamide‐adenine dinucleotide phosphate (NADPH) cofactor and the human HSD‐1 active site. The higher activation energy to dissociate that trimolecular interaction, compared to a bimolecular drug‐enzyme interaction characteristic of other HSD‐1 inhibitors, is posited to be responsible for the enzyme kinetic and favorable pharmacological properties of clofutriben.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Iowa, Iowa City, Iowa, USA.
- Scripps Clinic, La Jolla, California, USA.
- University of Illinois, Chicago, Illinois, USA.
- Eurofins Discovery, Taipei, Taiwan.
- IQVIA Laboratories, Indianapolis, Indiana, USA.
- Marmon Biostatistics, Seattle, Washington, USA.
ORCID-Profile: Guohua An, Cele Abad-Zapatero, David A Katz
Zitieren
APA
An, G., Gutierrez, J. A., Abad-Zapatero, C., Lin, S. K., Schmicker, C., Rinas, A., Engel, B., Magers, T., Marmon, T. K., & Katz, D. A. (2025). Human Adipose Tissue 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibition Without Tachyphylaxis by Clofutriben, a Pseudo‐Irreversible Enzyme Inhibitor. Clinical and Translational Science. https://doi.org/10.1111/cts.70398
Vancouver
An G, Gutierrez JA, Abad-Zapatero C, Lin SK, Schmicker C, Rinas A, et al. Human Adipose Tissue 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibition Without Tachyphylaxis by Clofutriben, a Pseudo‐Irreversible Enzyme Inhibitor. Clinical and Translational Science. 2025. doi:10.1111/cts.70398
BibTeX
@article{An2025,
author = {An, Guohua and Gutierrez, Julio A and Abad-Zapatero, Cele and Lin, Shin-Kai and Schmicker, Caleb and Rinas, Aimee and Engel, Brian and Magers, Tobias and Marmon, Tonya K and Katz, David A},
title = {Human Adipose Tissue 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibition Without Tachyphylaxis by Clofutriben, a Pseudo‐Irreversible Enzyme Inhibitor},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70398}
}
EUVIMED